深度聚焦！欧盟对华电动汽车加征关税引上汽集团强烈反对：呼吁欧盟慎重考虑，维护全球汽车产业链稳定

欧盟对华电动汽车加征关税引上汽集团强烈反对：呼吁欧盟慎重考虑，维护全球汽车产业链稳定

上海 - 2024年6月16日，针对欧盟委员会近日发布公告，拟对包括上汽集团在内的部分中国电动汽车生产商征收临时反补贴税，上汽集团今日发布声明表示，对欧盟委员会这一决定深表关切和遗憾，并呼吁欧盟慎重考虑其决定，与包括中国在内的全球汽车产业伙伴进行建设性的对话，共同寻找促进公平竞争和可持续发展的解决方案。

上汽集团指出，欧盟委员会的反补贴税决定不仅违背了市场经济原则和国际贸易规则，而且可能对全球汽车产业链的稳定和中欧经贸合作产生较大不利影响。

上汽集团：欧盟关税决定站不住脚

上汽集团表示，欧盟委员会的调查认定上汽集团从中国政府获得了不当补贴，这一结论站不住脚。上汽集团一直严格遵守中国和欧盟的法律法规，从未享受过任何政府补贴。

上汽集团还指出，欧盟委员会的反补贴税决定具有高度选择性，仅针对部分中国企业，这违背了公平竞争的原则。此外，欧盟委员会的调查过程缺乏透明度，相关企业没有得到充分的机会进行申辩。

欧盟关税措施将损害全球汽车产业链

上汽集团强调，欧盟委员会的反补贴税措施将对全球汽车产业链造成严重破坏。欧盟是全球最大的汽车市场之一，上汽集团等中国企业在欧盟市场拥有重要份额。欧盟加征关税将导致中国汽车出口成本大幅上升，迫使中国企业将生产转移到其他国家或地区，这将对欧盟汽车产业链的稳定造成严重冲击。

呼吁欧盟与中国进行建设性对话

上汽集团呼吁欧盟委员会慎重考虑其决定，撤销对中国电动汽车生产商的反补贴税措施。同时，上汽集团也希望与欧盟委员会及相关行业组织进行建设性的对话，共同寻找促进全球汽车产业链稳定和发展的解决方案。

上汽集团事件引发业界担忧

上汽集团事件引发了全球汽车产业界的广泛关注。业界人士普遍认为，欧盟委员会的反补贴税措施不仅会损害中国企业利益，也会对全球汽车产业链造成负面影响。

有专家指出，欧盟委员会的反补贴税措施是典型的贸易保护主义行为，将会阻碍全球自由贸易和经济全球化进程。

文章来源

• 上汽集团：欧盟委员会反补贴税决定可能对中欧经贸合作带来相对较大不利影响 https://www.yicai.com/brief/102148224.html
• 欧盟对华电动汽车加征关税意欲何为？ http://www.news.cn/world/20240416/fb8f0efddf9d40d3b076092cd4e200d2/c.html

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.